A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report-Reference-Cited by-同舟云学术

A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report

Published:2022-06-06 Issue:6 Volume:40 Page:1350-1353
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Wang Chunguang,Chen Shu,He Qianru,Sun Tingting,Xu Peiran

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-022-01262-2.pdf

Reference9 articles.

1. Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS et al (2015) Scientific Advances in Lung Cancer 2015. J Thorac Oncol 11(5):613–638. https://doi.org/10.1016/j.jtho.2016.03.012

2. Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, Sakao Y, Hida T, Yatabe Y (2016) Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol 34(28):3383–3389. https://doi.org/10.1200/JCO.2015.65.8732

3. Chaft JE, Dagogo-Jack I, Santini FC, Eng J, Yeap BY, Izar B, Chin E, Jones DR, Kris MG, Shaw AT et al (2018) Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer 122:67–71. https://doi.org/10.1016/j.lungcan.2018.05.020

4. Zeng J, Cui X, Cheng L, Chen Y, Du X, Sheng L (2020) Micropapillary pattern of stage IIIA-N(2) lung adenocarcinoma is a prognostic factor after adjuvant chemoradiotherapy. Future Oncol 16(36):3075–3084. https://doi.org/10.2217/fon-2020-0597

5. Cai C, Tang Y, Li Y, Chen Y, Tian P, Wang Y, Gong Y, Peng F, Zhang Y, Yu M et al (2021) Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients. Lung Cancer 152:104–108. https://doi.org/10.1016/j.lungcan.2020.12.018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel Intergenic Region (chr2: 30,316,870)-ALK Fusion in a Patient with Lung Adenocarcinoma Responding to Crizotinib Combined with Pemetrexed Treatment: A Case Report;OncoTargets and Therapy;2024-03

2. Traction force with extracellular matrix mediated by cytoskeleton influences metastasis through SLC8A1 induced Wnt-β-catenin pathway in endometrial cancer;Genes & Diseases;2023-09

3. Correction to: A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: A case report;Investigational New Drugs;2022-08-16